company background image
CSJA logo

CSL DB:CSJA Stock Report

Last Price

€85.00

Market Cap

€83.4b

7D

1.2%

1Y

-8.6%

Updated

28 May, 2024

Data

Company Financials +

CSJA Stock Overview

Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally.

CSJA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance4/6
Financial Health4/6
Dividends3/6

CSL Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CSL
Historical stock prices
Current Share PriceAU$85.00
52 Week HighAU$96.00
52 Week LowAU$67.50
Beta0.30
1 Month Change3.66%
3 Month Change0%
1 Year Change-8.60%
3 Year Change-6.08%
5 Year Change32.81%
Change since IPO241.37%

Recent News & Updates

Recent updates

Shareholder Returns

CSJADE BiotechsDE Market
7D1.2%-1.3%0.1%
1Y-8.6%-36.2%9.1%

Return vs Industry: CSJA exceeded the German Biotechs industry which returned -36.2% over the past year.

Return vs Market: CSJA underperformed the German Market which returned 9.1% over the past year.

Price Volatility

Is CSJA's price volatile compared to industry and market?
CSJA volatility
CSJA Average Weekly Movement3.0%
Biotechs Industry Average Movement6.1%
Market Average Movement4.9%
10% most volatile stocks in DE Market10.5%
10% least volatile stocks in DE Market2.5%

Stable Share Price: CSJA has not had significant price volatility in the past 3 months.

Volatility Over Time: CSJA's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
191632,065Paul McKenziewww.csl.com.au

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.

CSL Limited Fundamentals Summary

How do CSL's earnings and revenue compare to its market cap?
CSJA fundamental statistics
Market cap€83.44b
Earnings (TTM)€2.27b
Revenue (TTM)€13.03b

36.7x

P/E Ratio

6.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CSJA income statement (TTM)
RevenueUS$14.18b
Cost of RevenueUS$6.86b
Gross ProfitUS$7.32b
Other ExpensesUS$4.85b
EarningsUS$2.47b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Aug 13, 2024

Earnings per share (EPS)5.12
Gross Margin51.63%
Net Profit Margin17.43%
Debt/Equity Ratio54.4%

How did CSJA perform over the long term?

See historical performance and comparison

Dividends

1.3%

Current Dividend Yield

48%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.